GU Cancers 2021 | Promising therapies for bladder cancer
Sangeeta Goswami, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses novel therapies in development and on the horizon for the treatment of bladder cancer at ASCO GU 2021. The majority of novel therapies, such as enfortumab vedotin and FGFR-targeting therapies, are focused on the treatment of metastatic urothelial carcinoma, and the potential of these therapies in a neoadjuvant or adjuvant setting is yet to be explored. Dr Goswami discusses the benefits of combinatorial anti-CTLA-4 and anti-PD-1 therapy in the neoadjuvant setting, and summarizes the importance of the timing of therapies and the role of sequencing and prognostic markers in optimizing the treatment of patients with bladder cancer. This interview took place during the 2021 Genitourinary Cancers Symposium.
